GLTU but Inovio isn't a chart stock to us long term holders. If it were everyone would have seen these moves and be multi millionaires off of INO in the last month alone. Inovio moves to us based on catalysts, which starts next Monday presentation at the Cowen and Company 34th Annual Health Care Conference. INO surprises everyone. We have done our DD and say sell with caution...
So Here is why INO is up.
CEO Dr. Kim said INO will be the next Amgen or Gilead which would put INO between $400 and $600 per share.
Catalysts: 1st Half 2014 1. VGX-3100 results - Mid-2014 Cervical dysplasia Phase II study data 2. INO-3112 - Cervical Cancer 1H 2014 Initiate phase I/IIa 3. INO-3112 - Head and Neck Cancer 1H 2014 Initiate phase I/IIa 4. Prostate Cancer - initiate trial with Partner Roche 5. Initiate PENNVAX-GP phase I study
2014 2nd Half: 1. Initiate hTERT trials for: a. Lung cancer b. breast cancer c. Pancreatic cancer
2. Initiate HEP B - initiate trial with Roche 3. Initiate Malaria trials
Other potential catalysts: MERS, FLU, MRSA, Chikungunya virus, and Dengue fever.
World Vaccine Conference 2014 World's Largest Vaccine Conference & Expo March 24th-26th 2014 in Washington D.C. Speakers list: Dr. Sardesai Chief Operating Officer
Also, Dr. Anthony Ford Hutchinson of Inovio Scientific Advisory Board is speaking.
Day 2 - March 25 @ 10.49 Chairman's remarks Day 3 - March 26@ 11.29 Chairman's remarks @ 11.55 Use of Innovative technologies to address unmet needs for vaccines for viral diseases
I study and rely on technicals as well and can say emphatically that anyone who waits for a sub-$3.00 re-entry point is going to miss being a part of the incredible opportunity to own more shares of INO as it continues it's ascent. If there's a chance to re-enter below $3.35 I will be a buyer of more shares as low as it goes. GLTA!